Status:

WITHDRAWN

Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome

Lead Sponsor:

Mayo Clinic

Conditions:

Short Bowel Syndrome

Eligibility:

All Genders

18-85 years

Phase:

PHASE4

Brief Summary

We plan to examine the gastrointestinal (GI) physiologic profile of Exenatide, a glucagon-like peptide (GLP-1) analog as a possible intestino-trophic growth factor capable of inducing small bowel adap...

Eligibility Criteria

Inclusion

  • Patients with short bowel syndrome, between the ages of 18-85 who are dependent on parenteral nutrition for at least a year and are being closely followed by the Mayo Clinic Home Parenteral Nutrition Program (HPN) with at least one multisystem evaluation a year.

Exclusion

    Key Trial Info

    Start Date :

    March 1 2013

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    January 1 2014

    Estimated Enrollment :

    Patients enrolled

    Trial Details

    Trial ID

    NCT01818648

    Start Date

    March 1 2013

    End Date

    January 1 2014

    Last Update

    January 14 2014

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.